Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulodesine + allopurinol
- Development stage
- Phase 2
- Lead developer
- BioCryst Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of **ulodesine**, a purine nucleoside phosphorylase inhibitor, and **allopurinol**, a xanthine oxidase inhibitor. This combination is being investigated for the treatment of **gout** and **hyperuricemia**, particularly in patients who are not adequately controlled with allopurinol monotherapy or who have moderate renal insufficiency. Ulodesine inhibits purine nucleoside phosphorylase, reducing production of uric acid upstream of xanthine oxidase, while allopurinol inhibits xanthine oxidase, further reducing uric acid production. Together, they aim to more effectively lower serum uric acid levels than either agent alone.
- Other names
- ulodesine + allopurinol
02
Targets
PNP (Purine nucleoside phosphorylase)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on ulodesine + allopurinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulodesine + allopurinol.